Promacta and Ergocalciferol drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Promacta (eltrombopag olamine) and Ergocalciferol (ergocalciferol). Common drug interactions include dyspnoea among females and acute respiratory distress syndrome among males.

The phase IV clinical study analyzes what interactions people have when they take Promacta and Ergocalciferol. It is created by eHealthMe based on reports of 16 people who take the same drugs from the FDA, and is updated regularly.

What is Promacta?

Promacta has active ingredients of eltrombopag olamine. It is often used in idiopathic thrombocytopenic purpura (itp). eHealthMe is studying from 17,758 Promacta users. Check the latest studies of Promacta.

What is Ergocalciferol?

Ergocalciferol has active ingredients of ergocalciferol. It is often used in rickets. eHealthMe is studying from 32,652 Ergocalciferol users. Check the latest studies of Ergocalciferol.

On Jul, 18, 2026

16 people who take Promacta and Ergocalciferol together, and have interactions are studied.

Promacta and Ergocalciferol drug interactions.

What are the common drug interactions of Promacta and Ergocalciferol, by gender? *:

female:

Dyspnoea (difficult or laboured respiration)
Platelet count decreased
Asthenia (weakness)
Bacterial infection
Confusional state
Death
Disease progression
Gastric haemorrhage (bleeding stomach)
Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
Hospitalisation

male:

Acute respiratory distress syndrome
Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure)
Platelet disorder
Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down)
Sepsis (a severe blood infection that can lead to organ failure and death)
Tachycardia (a heart rate that exceeds the range of 100 beats/min)
Tachypnoea (a condition of rapid breathing over 20 per minute)
Thermal burn (burn by heat)
Thrombocytopenia (decrease of platelets in blood)
Disseminated intravascular coagulation (systemic activation of blood coagulation)

What are the common drug interactions of Promacta and Ergocalciferol, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Hospitalisation

50-59:

Febrile neutropenia (fever with reduced white blood cells)
Myelodysplastic syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged)

60+:

Dyspnoea (difficult or laboured respiration)
Platelet count decreased
Gastric haemorrhage (bleeding stomach)
Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
Haemoglobin decreased
Hypersensitivity
Hypotension (abnormally low blood pressure)
Influenza
Lobar pneumonia (a form of pneumonia that affects a large and continuous area of the lobe of a lung)
Metabolic acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body)

What are the existing conditions these people have? *

Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 2 people, 12.50%
Thrombocytopenia (decrease of platelets in blood): 1 person, 6.25%
Hypogonadism (reduction or absence of hormone secretion or other physiological activity of the gonads (testes or ovaries)): 1 person, 6.25%
Aplastic Anemia: 1 person, 6.25%
Chronic Kidney Disease: 1 person, 6.25%
Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 1 person, 6.25%
Diabetic Complication: 1 person, 6.25%
Hepatitis B: 1 person, 6.25%
Hepatitis C: 1 person, 6.25%
Idiopathic Thrombocytopenic Purpura (bleeding disorder in which the immune system destroys platelets, which are necessary for normal blood clotting): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Promacta and Ergocalciferol?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously